var data={"title":"Potassium iodide (SSKI, Thyroshield): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Potassium iodide (SSKI, Thyroshield): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6816?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=potassium-iodide-sski-thyroshield-patient-drug-information\" class=\"drug drug_patient\">see &quot;Potassium iodide (SSKI, Thyroshield): Patient drug information&quot;</a> and <a href=\"topic.htm?path=potassium-iodide-sski-thyroshield-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Potassium iodide (SSKI, Thyroshield): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211985\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>iOSAT [OTC];</li>\n      <li>SSKI;</li>\n      <li>ThyroSafe [OTC];</li>\n      <li>ThyroShield [OTC] [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212014\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antidote;</li>\n      <li>\n        Antithyroid Agent;</li>\n      <li>\n        Expectorant</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211987\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Expectorant (SSKI):</b> Oral: 300 to 600 mg (0.3 to 0.6 mL) 3 to 4 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Antidote [thyroid block following nuclear radiation emergency (iOSAT, ThyroSafe, ThyroShield)]: Includes pregnant/lactating women:</b> Oral: 130 mg once daily, continue for 10 to 14 days or as directed by public officials (until risk of exposure has passed or other measures are implemented)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Thyroidectomy preparation (off-label use):</b> Oral: 50 to 100 mg (1 to 2 drops <b>or</b> 0.05 to 0.1 mL SSKI) 3 times daily; administer for 10 days before surgery; if not euthyroid prior to surgery, consider concurrent beta-blockade (eg, propranolol) in the immediate preoperative period to reduce the risk of thyroid storm (Ross 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Sporotrichosis (cutaneous, lymphocutaneous; off-label use) (SSKI):</b> Oral: Initial: 5 drops 3 times daily; increase to 40 to 50 drops 3 times daily as tolerated until 2 to 4 weeks after lesions have resolved (usual duration 3 to 6 months) (Kauffman 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Thyroid gland protection during radiopharmaceutical use (off-label use):</b> Oral: Tablet: 130 mg once daily <b>or</b> Solution (SSKI): 4 drops 3 times daily (Bexxar prescribing information 2012). <b>Note:</b> Begin at 1 to 48 hours prior to exposure. Continue potassium iodide after radiopharmaceutical administration until risk of exposure has diminished (treatment duration and time of initiation is dependent on the radiopharmaceutical, consult specific protocol).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Thyrotoxic crisis/thyroid storm (off-label use):</b> Oral: <b>Note:</b> Administer at least 1 hour after antithyroid drug administration (eg, propylthiouracil, methimazole): SSKI 250 mg (5 drops <b>or</b> 0.25 mL) every 6 hours (Ross 2016)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212001\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=potassium-iodide-sski-thyroshield-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Potassium iodide (SSKI, Thyroshield): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Antidote [thyroid block following nuclear radiation emergency (iOSAT, ThyroSafe, ThyroShield)]:</b> Infants, Children, and Adolescents: Dosing should continue for 10 to 14 days or as directed by public officials (until risk of exposure has passed or other measures are implemented): Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants &le;1 month: 16.25 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants &gt;1 month to Children &le;3 years: 32.5 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &gt;3 to &le;12 years: 65 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &gt;12 years and Adolescents weighing &lt;68 kg: 65 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &gt;12 years and Adolescents weighing &ge;68 kg: 130 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Sporotrichosis (cutaneous, lymphocutaneous) (off-label use) (SSKI):</b> Children and Adolescents: Oral: Initial: 50 mg (1 drop <b>or</b> 0.05 mL) 3 times daily; increase as tolerated up to a maximum of 2,500 mg (50 drops <b>or</b> 2.5 mL) <b>or</b> 1 drop/kg (0.05 mL/kg) 3 times daily, whichever is lower; continue for 2 to 4 weeks after lesions have resolved (usual duration: 3 to 6 months) (Kauffman 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Thyroidectomy preparation (off-label use) (SSKI):</b> Children and Adolescents: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Patients unable to receive concurrent antithyroid therapy: 150 to 350 mg (3 to 7 drops <b>or</b> 0.15 to 0.35 mL) 3 times daily (Ross 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Patients receiving concurrent antithyroid therapy: 50 to 100 mg (1 to 2 drops or 0.05 to 1 mL) 3 times daily (Ross 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Administer SSKI for 10 days before surgery. If patient is not euthyroid prior to surgery, consider concurrent beta-blockade (eg, propranolol) in the immediate preoperative period to reduce the risk of thyroid storm.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Thyroid gland protection during radiopharmaceutical use (off-label use):</b> Infants, Children, and Adolescents: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants &lt;5 kg: 16 mg once daily (Giammarile 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children 1 month to 3 years or 5 to 15 kg: 32 mg once daily (Giammarile 2008; Olivier 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents 3 to 13 years or 15 to &lt;50 kg: 65 mg once daily (Giammarile 2008; Olivier 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents &gt;13 years or &ge;50 kg: 130 mg once daily (Giammarile 2008; Olivier 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Begin at 1 to 48 hours prior to exposure. Continue potassium iodide after radiopharmaceutical administration until risk of exposure has diminished (treatment duration and time of initiation is dependent on the radiopharmaceutical, consult specific protocol.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Thyrotoxic crisis/thyroid storm (off-label use):</b> Oral: <b>Note:</b> Administer preferably 2 hours after antithyroid drug administration:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants: SSKI 100 mg (2 drops <b>or</b> 0.1 mL) 4 times daily (Eyal 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children: SSKI 250 mg (5 drops <b>or</b> 0.25 mL) 2 to 4 times daily (Eyal 2008)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211988\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16562921\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16562922\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211963\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">SSKI: 1 g/mL (30 mL, 237 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ThyroShield: 65 mg/mL (30 mL [DSC]) [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40, methylparaben, propylene glycol, propylparaben, saccharin sodium; black raspberry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Generic: 65 mg/mL (30 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">iOSAT: 130 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ThyroSafe: 65 mg [scored]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13755335\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211965\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SSKI: Dilute in a glassful of water, fruit juice, or milk. Administer with food or milk to decrease gastric irritation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">iOSAT, Thyrosafe, Thyroshield: Administer as soon as possible after instructed to do so by public officials. Do not take more than 1 dose in 24 hours. Tablets may be administered whole or crushed and then mixed with water, low fat milk (white or chocolate), orange juice, soda (flat), raspberry syrup, or infant formula. Raspberry syrup disguises the taste best; low-fat white milk or water do not hide the salty taste well) (AAP 2003). See Extemporaneously Prepared.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211964\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Antidote:</b> Block thyroidal uptake of radioactive isotopes of iodine in a nuclear radiation emergency.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Expectorant:</b> Expectorant for the symptomatic treatment of chronic pulmonary diseases complicated by mucous.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25471004\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Graves hyperthyroidism (following radioactive iodine therapy); Sporotrichosis (cutaneous, lymphocutaneous); Thyroidectomy preparation; Thyroid gland protection during radiopharmaceutical use; Thyrotoxic crisis/thyroid storm</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F802361\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Potassium iodide products, including saturated solution of potassium iodide (SSKI) may be confused with potassium iodide and iodine (Strong Iodide Solution or Lugol's solution)</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Dosage volume: Dosing errors have been reported during the prescribing, dispensing, and administration of potassium iodide-containing solutions (eg, Lugol&rsquo;s, SSKI). Errors have occurred when <b>mL</b> doses were administered, when only <b>drops</b> were indicated for the dose. Carefully review dosage and administration information; appropriate oral dosage is most commonly expressed as drops to provide doses less than 1 mL. Dispensing unit doses is also highly recommended; pharmacists should never dispense quantities that could be lethal if consumed as a single dose. (ISMP, 2011).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211954\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Cardiac arrhythmias, numbness, vasculitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Confusion, fatigue, fever, numbness, tingling sensation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Acne vulgaris, dermatitis, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Goiter, hyperthyroidism (prolonged use), hypothyroidism (prolonged use), myxedema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Diarrhea, enlargement of salivary glands, gastric distress, gastrointestinal hemorrhage, gingival pain, metallic taste, nausea, stomach pain, toothache, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Eosinophilia, lymphedema, thyroid adenoma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Hypersensitivity reaction (angioedema, cutaneous and mucosal hemorrhage, serum sickness-like symptoms)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthralgia, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Dyspnea, rhinitis, wheezing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Iodine poisoning (with prolonged treatment/high doses)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211969\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to iodide, iodine, or any component of the formulation; dermatitis herpetiformis; hypocomplementemic vasculitis, nodular thyroid condition with heart disease</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211951\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Iodide hypersensitivity may occur, manifesting as angioedema, cutaneous/mucosal hemorrhage, and serum sickness-like symptoms (fever, arthralgia, lymph node enlargement, and eosinophilia).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Skin reactions: Can cause acne flare-ups and/or dermatitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid adverse effects: Prolonged use may lead to hypothyroidism. Iodide may cause underactive or overactive thyroid; thyroid enlargement may also occur. Use with caution in patients with a history of hyperthyroidism; use is contraindicated in patients with nodular thyroid condition (goiter) with heart disease. Iodism or chronic iodide poisoning may occur with high doses or prolonged treatment; symptoms include burning of mouth/throat, sore teeth/gums, severe headache, metallic taste, eye irritation/eye lid swelling, increased salivation, acneform skin lesions, and (rarely) severe skin lesions;  withhold potassium iodide treatment and manage with supportive care.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenal insufficiency: Use with caution in patients with Addison disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bronchitis: Use with caution in patients with acute bronchitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiac disease: Use with caution in patients with cardiac disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myotonia congenita: Use with caution in patients with myotonia congenita.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tuberculosis: Use with caution in patients with tuberculosis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: In a nuclear radiation emergency, infants and children are more likely to experience thyroid damage.  Neonates &lt;1 month are at higher risk for hypothyroidism with potassium iodide use; evaluate thyroid function if repeat dosing is required in this patient population.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: For thyroid gland protection (radiopharmaceutical use), potassium iodide must be administered prior to receiving radiopharmaceuticals that require thyroid gland protection. For nuclear radiation emergency, take only when instructed by public health officials; do not take more or more often than instructed; follow other emergency measures recommended by officials.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299922\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211956\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9798&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aliskiren: Potassium Salts may enhance the hyperkalemic effect of Aliskiren. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin II Receptor Blockers: Potassium Salts may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin-Converting Enzyme Inhibitors: Potassium Salts may enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Antithyroid Agents may increase the serum concentration of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eplerenone: May enhance the hyperkalemic effect of Potassium Salts. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heparin: May enhance the hyperkalemic effect of Potassium Salts.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heparins (Low Molecular Weight): May enhance the hyperkalemic effect of Potassium Salts.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: Potassium Iodide may enhance the hypothyroid effect of Lithium. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hyperkalemic effect of Potassium Salts.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium-Sparing Diuretics: Potassium Salts may enhance the hyperkalemic effect of Potassium-Sparing Diuretics. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Iodide I131: Antithyroid Agents may diminish the therapeutic effect of Sodium Iodide I131.  Management: Discontinue antithyroid therapy 3-4 days prior to sodium iodide I-131 administration.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Antithyroid Agents may increase the serum concentration of Theophylline Derivatives. <b> Exceptions: </b>Dyphylline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Antithyroid Agents may diminish the anticoagulant effect of Vitamin K Antagonists. <i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211959\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211973\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Iodide crosses the placenta (may cause hypothyroidism and goiter in fetus/newborn). Use as an expectorant during pregnancy is contraindicated by the AAP (AAP 1976). Use for protection against thyroid cancer secondary to radioactive iodine exposure is considered acceptable based upon risk:benefit, keeping in mind the dose and duration (AAP 2003). In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey, 2003). Pregnant women should take as instructed by public officials and contact their physician. Repeat dosing should be avoided if possible (AAP 2003). Refer to Iodine monograph for additional information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211974\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Potassium iodide is excreted in breast milk. May cause skin rash and thyroid suppression in nursing infant. Nursing mothers should take as instructed by public officials and contact their physician (AAP 2003). Refer to Iodine monograph for additional information. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211961\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Thyroid function tests (thyroid function should be monitored in pregnant or breast-feeding women, neonates, and young infants if repeat doses are required following radioactive iodine exposure); signs/symptoms of hypo- or hyperthyroidism</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211950\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Reduces viscosity of mucus by increasing respiratory tract secretions; inhibits secretion of thyroid hormone, fosters colloid accumulation in thyroid follicles. Following radioactive iodine exposure, potassium iodide blocks the uptake of radioactive iodine by the thyroid, reducing the risk of thyroid cancer. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211968\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Hyperthyroidism: 24 to 48 hours (Nayak 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peak effect: Hyperthyroidism: ~2 weeks after continuous therapy (Nayak 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Radioactive iodine exposure: Each dose has a duration of ~24 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211972\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Potassium Iodide (Antidote) Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">65 mg/mL (30 mL): $16.74</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (SSKI Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g/mL (30 mL): $354.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038775\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Cato-Bell (IN);</li>\n      <li>Iodid (BE);</li>\n      <li>Iodure de Potassium (FR);</li>\n      <li>Ioduro Potasico Rovi (ES);</li>\n      <li>Jodam (PL);</li>\n      <li>Jodetten Henning (DE);</li>\n      <li>Jodgamma (DE);</li>\n      <li>Jodid (DE, HU, LU, PL);</li>\n      <li>Jodid Merck (AT);</li>\n      <li>Jodid Verla (DE);</li>\n      <li>Jodid-ratiopharm (DE);</li>\n      <li>Jodix (FI);</li>\n      <li>Jodostin (PL);</li>\n      <li>Jodox (PL);</li>\n      <li>Kalium jodatum (DE);</li>\n      <li>Kaliumiodid (CH);</li>\n      <li>Kaliumiodid BC (DE);</li>\n      <li>Kaliumjodid Lannacher (AT);</li>\n      <li>Kaliumjodid Recip (SE);</li>\n      <li>Kaliumjodid &rdquo;Dak&rdquo; (DK);</li>\n      <li>Mono-Jod (DE);</li>\n      <li>Tarjod (PL);</li>\n      <li>Thyroprotect (DE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &quot;Adverse Reactions to Iodide Therapy of Asthma and Other Pulmonary Diseases,&quot; <i>Pediatrics</i>, 1976, 57(2):272-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-iodide-sski-thyroshield-drug-information/abstract-text/1250663/pubmed\" target=\"_blank\" id=\"1250663\">1250663</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP), Committee on Drugs. Adverse reactions to iodide therapy of asthma and other pulmonary diseases. <i>Pediatrics</i>. 1976;57(2):272-274.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-iodide-sski-thyroshield-drug-information/abstract-text/1250663 /pubmed\" target=\"_blank\" id=\"1250663 \">1250663 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;American Academy of Pediatrics Committee on Environmental Health. Radiation Disasters and Children,&rdquo; <i>Pediatrics</i>, 2003, 111(6 Pt 1):1455-66.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bexxar (tositumomab and iodine I 131 tositumomab) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; August 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bailey B, &quot;Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?&quot; <i>Birth Defects Res A Clin Mol Teratol</i>, 2003, 67(2):133-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-iodide-sski-thyroshield-drug-information/abstract-text/12769509/pubmed\" target=\"_blank\" id=\"12769509\">12769509</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"Eyal.2008\"></a>Eyal O and Rose SR, &ldquo;Thyroid Disease,&rdquo; in <i>Roger&rsquo;s Textbook of Pediatric Intensive Care</i>, 4th ed, David G Nichols, ed, Philadelphia, PA: Lippincott, Williams, &amp; Wilkins, 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Giammarile F, Chiti A, Lassmann M, et al, &ldquo;EANM Procedure Guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) Therapy,&rdquo; <i>Eur J Nucl Med Mol Imaging</i>, 2008, 35(5):1039-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-iodide-sski-thyroshield-drug-information/abstract-text/18274745/pubmed\" target=\"_blank\" id=\"18274745\">18274745</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute for Safe Medication Practices (ISMP), &ldquo;Look out for Lugol&rsquo;s...Error-prevention strategies for this strong iodine solution,&rdquo; ISMP Medication Safety Alert, December 1, 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Iosat (potassium iodide tablets) [prescribing information]. Livingston, NJ: Anbex Inc; August 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kauffman CA, Bustamante B, Chapman SW, et al, &ldquo;Clinical Practice Guidelines for the Management of Sporotrichosis: 2007 Update by the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2007, 45(10):1255-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-iodide-sski-thyroshield-drug-information/abstract-text/17968818/pubmed\" target=\"_blank\" id=\"17968818\">17968818</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nayak B and Burman K, &ldquo;Thyrotoxicosis and Thyroid Storm,&rdquo; <i>Endocrinol Metab Clin North Am</i>, 2006,35(4):663-86, vii.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-iodide-sski-thyroshield-drug-information/abstract-text/17127140/pubmed\" target=\"_blank\" id=\"17127140\">17127140</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Olivier P, Colarinha P, Fettich J, et al, &ldquo;Guideline for Radioiodinated MIBG Scintigraphy in Children,&rdquo; <i>Eur J Nucl Med Mol Imaging</i>, 2003, 30(5):B45-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-iodide-sski-thyroshield-drug-information/abstract-text/12658506/pubmed\" target=\"_blank\" id=\"12658506\">12658506</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27521067\"></a>Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. <i>Thyroid</i>. 2016;26(10):1343-1421.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-iodide-sski-thyroshield-drug-information/abstract-text/27521067/pubmed\" target=\"_blank\" id=\"27521067\">27521067</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"6688081\"></a>Ross DS, Daniels GH, De Stefano P, Maloof F, Ridgway EC. Use of adjunctive potassium iodide after radioactive iodine (131I) treatment of Graves' hyperthyroidism. <i>J Clin Endocrinol Metab</i>. 1983;57(2):250-253.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-iodide-sski-thyroshield-drug-information/abstract-text/6688081/pubmed\" target=\"_blank\" id=\"6688081\">6688081</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25178068\"></a>Sato S, Noh JY, Sato S, et al. Comparison of efficacy and adverse effects between methimazole 15 mg+inorganic iodine 38 mg/day and methimazole 30 mg/day as initial therapy for Graves' disease patients with moderate to severe hyperthyroidism. <i>Thyroid</i>. 2015;25(1):43-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-iodide-sski-thyroshield-drug-information/abstract-text/25178068/pubmed\" target=\"_blank\" id=\"25178068\">25178068</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    SSKI (potassium iodide) [prescribing information]. Maple Grove, MN: Upsher-Smith; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ThyroSafe (potassium iodide) [prescribing information]. Honey Brook, PA: Recipharm Inc; May 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ThyroShield (potassium iodide) [prescribing information]. Fenton, MO: Fleming &amp; Co; December 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Food and Drug Administration (FDA). FDA's guidance on protection of children and adults against thyroid cancer in case of nuclear accident. FDA Talk Paper; issued December 2001. Available at <a href=\"http://www.fda.gov/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/ucm133711.htm\" target=\"_blank\">http://www.fda.gov/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/ucm133711.htm</a></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9798 Version 106.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F211985\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F212014\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F211987\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F212001\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F211988\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F16562921\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F16562922\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F211963\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F13755335\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F211965\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F211964\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25471004\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F802361\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F211954\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F211969\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F211951\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299922\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F211956\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F211959\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F211973\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F211974\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F211961\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F211950\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F211968\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F211972\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038775\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9798|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=potassium-iodide-sski-thyroshield-patient-drug-information\" class=\"drug drug_patient\">Potassium iodide (SSKI, Thyroshield): Patient drug information</a></li><li><a href=\"topic.htm?path=potassium-iodide-sski-thyroshield-pediatric-drug-information\" class=\"drug drug_pediatric\">Potassium iodide (SSKI, Thyroshield): Pediatric drug information</a></li></ul></div></div>","javascript":null}